Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies

Publications

A phase I study of pazopanib in combination with FOLFOX 6 or capeOx in subjects with colorectal cancer

Brady J. et al, (2009), JOURNAL OF CLINICAL ONCOLOGY, 27

Phase II trial of nemorubicin hydrocloride (nemorubicin) in combination with cisplatin (cDDP) in patients (pts) with hepatocellular carcinoma (HCC): First step results

Izzo F. et al, (2009), JOURNAL OF CLINICAL ONCOLOGY, 27

Phase II trial of nemorubicin hydrocloride (nemorubicin) in combination with cisplatin (cDDP) in patients (pts) with hepatocellular carcinoma (HCC): First step results.

Izzo F. et al, (2009), J Clin Oncol, 27

Cells deficient in the base excision repair protein, DNA polymerase beta, are hypersensitive to oxaliplatin chemotherapy: A scientific rationale for chemo-radiation treatment

Nicolay N. et al, (2009), CANCER RESEARCH, 69

A phase I study of extended dosing with lomeguatrib with temozolomide in patients with advanced melanoma.

Kefford RF. et al, (2009), Br J Cancer, 100, 1245 - 1249

O(6)-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatrib.

Watson AJ. et al, (2009), Br J Cancer, 100, 1250 - 1256

Cancer of the Colon and Rectum: Treatment: Novel therapies

Escriu C. et al, (2009), 359 - 366

Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors.

Plummer R. et al, (2008), Clin Cancer Res, 14, 7917 - 7923

Phase I study of copper-binding agent ATN-224 in patients with advanced solid tumors.

Lowndes SA. et al, (2008), Clin Cancer Res, 14, 7526 - 7534

ADJUVANT BEVACIZUMAB IS SAFE TREATMENT FOR MELANOMA PATIENTS AT HIGH RISK OF RECURRENCE

Biswas S. et al, (2008), ANNALS OF ONCOLOGY, 19, 245 - 245

High-intensity focused ultrasound ablation of liver tumours: can radiological assessment predict the histological response?

Leslie TA. et al, (2008), Br J Radiol, 81, 564 - 571

Phase I pharmacokinetic and pharmacodynamic study of the prenyl transferase inhibitor AZD3409 in patients with advanced cancer.

Appels NMGM. et al, (2008), Br J Cancer, 98, 1951 - 1958

A phase II study of PTK787 in metastatic melanoma patients.

Corrie P. et al, (2008), J Clin Oncol, 26

A phase II study of PTK787 in metastatic melanoma patients

Corrie P. et al, (2008), JOURNAL OF CLINICAL ONCOLOGY, 26

A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer.

Khan OA. et al, (2008), Br J Cancer, 98, 1614 - 1618

AZD6244 (ARRY-142886) vs temozolomide (TMZ) in patients (pts) with advanced melanoma: An open-label, randomized, multicenter, phase II study.

Dummer R. et al, (2008), J Clin Oncol, 26

AZD6244 (ARRY-142886) vs temozolomide (TMZ) in patients (pts) with advanced melanoma: An open-label, randomized, multicenter, phase II study

Dummer R. et al, (2008), JOURNAL OF CLINICAL ONCOLOGY, 26

Inhibition of O-6-methylguanine DNA methyltransferase (MGMT) in solid tumors by lomeguatrib

Sabharwal A. et al, (2008), JOURNAL OF CLINICAL ONCOLOGY, 26

Nemorubicin hydrochloride (nemorubicin) in combination with cisplatin (cDDP): Phase I in patients (pts) with hepatocellular carcinoma (HCC)

Fiore F. et al, (2008), JOURNAL OF CLINICAL ONCOLOGY, 26

Nemorubicin hydrochloride (nemorubicin) in combination with cisplatin (cDDP): Phase I in patients (pts) with hepatocellular carcinoma (HCC).

Fiore F. et al, (2008), J Clin Oncol, 26